Kymera Therapeutics vs Septerna
Septerna is the larger business, with $46.0m of revenue in fiscal 2025 against $39.2m for Kymera Therapeutics (1.2 times as much). Septerna grew faster (4174.5% against -16.7%). Septerna kept more of each dollar of sales as profit: a net margin of -106.4% against -794.0%. Kymera Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Kymera TherapeuticsKYMR, 2025 | SepternaSEPN, 2025 |
|---|---|---|
| Revenue | $39.2m | $46.0m |
| Revenue growth | -16.7% | 4174.5% |
| Net income | −$311m | −$48.9m |
| Operating margin | -891.1% | -148.6% |
| Net margin | -794.0% | -106.4% |
| Return on equity | -25.8% | -12.2% |
| Free cash flow | −$234m | $110m |
| Cash | $357m | $121m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 238 | 130 |
| Market value | $10.94bn | $1.98bn |
| Price vs our value range | — | Above our value range |
| Moat score | 14 (Weak) | — |
| Insider trades, 12 months | 2 buys, 274 sales | 0 buys, 28 sales |